Novabay Pharmaceuticals (NBY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Sales | 521 | 0 | 0 | 0 | 0 |
| Cost of Goods | 479 | N/A | N/A | N/A | N/A |
| Gross Profit | 42 | N/A | N/A | N/A | N/A |
| Operating Expenses | 1,777 | 1,891 | 3,290 | 10,009 | 1,703 |
| Operating Income | -1,256 | -1,891 | -3,290 | -228 | -1,703 |
| Other Income | -77 | -73 | -40 | -54 | -151 |
| Pre-tax Income | -1,333 | -1,964 | -3,330 | -282 | -1,854 |
| Net Income Continuous | -1,333 | -1,964 | -3,330 | -282 | -1,854 |
| Net Income Discontinuous | 40 | 42 | 11,000 | -930 | 642 |
| Net Income | $-1,293 | $-1,922 | $7,670 | $-1,212 | $-1,212 |
| EPS Basic Total Ops | -0.22 | -0.33 | 1.44 | 30.71 | -1.92 |
| EPS Basic Continuous Ops | -0.23 | -0.34 | -0.63 | 29.35 | -2.48 |
| EPS Basic Discontinuous Ops | 0.01 | 0.01 | 2.07 | 1.36 | 0.56 |
| EPS Diluted Total Ops | -0.22 | -0.33 | 1.42 | 30.71 | -1.92 |
| EPS Diluted Continuous Ops | -0.23 | -0.34 | -0.61 | 29.35 | -2.48 |
| EPS Diluted Discontinuous Ops | 0.01 | 0.01 | 2.03 | 1.36 | 0.56 |
| EPS Diluted Before Non-Recurring Items | -0.23 | -0.34 | -0.61 | N/A | -0.60 |
| EBITDA(a) | $-578 | $-1,890 | $-3,288 | $-9,993 | $-1,697 |